AstraZeneca says it can 'absorb impact' of US pricing deal Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 6 November, 2025

Bring your rare disease drug to the Japanese market — join PMDA officials to map the path forward. Find out how — get your spot.

presented by De­sign­ing for scal­a­bil­i­ty from day one: iRe­gene's foun­da­tion­al tech un­locks com­mer­cial cell ther­a­pies

news Moderna struggles to sell its vaccines, posts paltry RSV sales in third quarter Lilly's amylin moves to Phase 3 after success in next obesity drug wave AstraZeneca reports record-breaking quarter, says it can 'absorb impact' of US pricing deal China lifts import ban on Illumina's DNA sequencers as trade tensions ease

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Start your year where biopharma sets its agenda. Join Endpoints News and industry leaders in San Francisco as we unpack the forces shaping dealmaking, China's emerging role and regulatory shifts. Save $200 with Early Bird rates — reserve your spot today.

endpoints pharma Delaware judge refuses to block Metsera from ending Pfizer obesity deal •  FTC raises concerns about structure of Novo Nordisk's bid for Metsera FDA reviewers were divided over Stealth's data before Barth drug approval, documents show Soleno's stock drops despite rise in Prader-Willi drug sales Supernus halts delivery of some Parkinson’s pumps over supply constraints Teva CEO says IRA drug price talks were 'consistent' with expectations, details new search for API sale NIH, universities clash in appeals court over payment cut plan Exclusive: Ex-Illumina and Grail employees raise $6.7M to spot liver disease

in case you missed it 1. FDA rejects Biohaven's ataxia drug, shutting down company's second attempt to win approval 2. ‘Not the end of the story:’ Nobel laureate David Baker on what’s next for de novo design after RFantibody lands in Nature 3. Recursion CEO Chris Gibson to step down as pressure builds to deliver in the clinic